About this trial
The objective of this clinical trial is to determine whether a Photoacoustic flow cytometry (PAFC)-based prototype device can detect circulating tumor cells (CTCs) in the blood of melanoma patients in vivo, in real time, and do so at detection limits at least one order of magnitude below the detection limits of currently existing ex vivo methods.
Eligibility criteria
Qualifiers
Age 18 to 80 years
Histological documented diagnosis of melanoma
Signed informed consent form approved by the University of Arkansas for Medical Sciences (UAMS) Institutional Review Board (IRB)
Must be able to sit still for 90 minutes
Disqualifiers
Active infection
Current and significant medical or surgical condition as determined by the Investigator
Diagnosis or evidence of organic brain syndrome
Pregnancy or breastfeeding
Trial design
Treatments tested in this trial
- Not listed